Folic acid synthesis enzyme

Folic acid synthesis enzymes are a group of metabolic enzymes responsible for the biosynthesis and utilization of folate (vitamin B9) and its reduced derivatives, crucial for the cellular transfer of one-carbon units in reactions essential for nucleic acid (DNA, RNA) synthesis, amino acid metabolism (methionine, serine, glycine, histidine), and methylation reactions involved in epigenetic regulation[1][3][4][7]. Major enzymes in this group include dihydrofolate reductase (DHFR; catalyzes the reduction of dihydrofolate to tetrahydrofolate), serine hydroxymethyltransferase, methylenetetrahydrofolate dehydrogenase, methionine synthase, folylpolyglutamate synthase, and γ-glutamyl hydrolase[1][4][7]. Inhibition of folic acid synthesis enzymes by drugs (notably DHFR inhibitors like methotrexate, trimethoprim, pyrimethamine, and sulfonamides that interfere with dihydropteroate synthetase) is an important therapeutic strategy for treating cancer, bacterial infections, protozoal infections, and for certain immunosuppressive applications[1][5][7]. Aberrations in this pathway underlie a wide range of diseases, from malignancies (due to increased proliferative demand) to birth defects (neural tube defects from deficiency or inhibition), and cardiovascular/neurodegenerative disorders (via hyperhomocysteinemia and impaired methylation)[3][7]. "Folic acid synthesis enzyme" refers to a group, not a single molecule, so the entry is considered too broad and non-specific for canonical drug target designation.

Other names

Folate pathway enzymeFolate biosynthetic enzymeFolate metabolic enzymeOne-carbon metabolism enzyme

Inhibition of dihydrofolate reductase (DHFR); Inhibition of dihydropteroate synthetase (by sulfonamides, competitively inhibits PABA in folate pathway); Disruption of one-carbon transfer reactions and nucleotide synthesis